MyOme, a leading genomics innovation and risk modeling company, today announced the appointment of Sam Roosz and Dr. Ravi Thadhani to its Board of Directors. The two executives bring deep expertise ...

In a major step toward expanding patient access, MyOme is highlighting its strategic partnership with Natera (NASDAQ: NTRA) to launch Zenith™ powered by MyOme. Zenith is a premium exome and genome ...

MyOme’s Rare Disease diagnostic product addresses these challenges by providing a more comprehensive WGS-based approach, promoting efficient and accurate diagnosis, leading to improved patient ...

The new joint initiative with The Partner Collective® by Collective Health® will allow employers to empower their workforces with MyOme's lifelong genomic insights to support preventative care and ...

MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ — MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary artery ...

Integrated polygenic risk score more accurately identified individuals at elevated risk for developing coronary artery disease, especially within borderline or intermediate clinical risk categories ...

MyOme, Inc., a leading clinical genetics innovation company, and Broad Clinical Labs (BCL), the world expert in whole genome sequencing (WGS) are announcing a partnership to support the Southern ...

Menlo Park-based MyOme, a clinical whole genome analysis company helping families understand their risk for diseases, has announced the expansion of its rare disease test to include tandem repeat ...

MENLO PARK, Calif., April 21, 2026 /PRNewswire/ -- MyOme, a leading genomics innovation and risk modeling company, today announced the appointment of Sam Roosz and Dr. Ravi Thadhani to its Board of ...